Zoetis was created in 2013 after splitting off from Pfizer’s animal health division. While it may not seem like a household ...

Stifel Financial analysts downgraded Zoetis (ZTS) stock from a Buy to a Hold rating on Wednesday, citing slower growth over ...

U.S. equities rose at midday ahead of the latest announcement from the Federal Reserve, as President Donald Trump again ...

Stifel downgraded Zoetis (NYSE:ZTS) to Hold from Buy, warning that revenue growth could fall short of Wall Street expectations in the next two years as competition intensifies across key product ...

Zoetis Inc. closed 19.30% below its 52-week high of $200.33, which the company achieved on September 19th.

In the latest trading session, Zoetis (ZTS) closed at $155.06, marking a -4.09% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.03%. Meanwhile, the ...

Zoetis published its 2024 Sustainability Progress Update "Advancing Sustainability in Animal Health for a Better Future" to ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.

Zoetis Inc. closed 17.97% short of its 52-week high of $200.33, which the company reached on September 19th.

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal ...